How do you choose between darolutamide and abiraterone when adding to docetaxel plus ADT in management of castrate sensitive high burden metastatic prostate cancer?

How do you manage systemic therapy for patients with castrate sensitive high burden metastatic prostate cancer?

• ADT alone
• ADT + Docetaxel
• ADT + Abiraterone/Prednisone
• ADT + tesosterone receptor antagonist (enzalutamide, apalutamide)
• ADT + Docetaxel + Abiraterone/Prednisone
• ADT + Docetaxel + Darolutamide
• Other